| Pay vs Performance Disclosure | 12 Months Ended |
| Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) |
| Pay vs Performance Disclosure [Table] | | | |
| Pay vs Performance [Table Text Block] | Value of Initial Fixed $100 Investment Based on Summary Average Summary Average Peer Group Compensation Compensation Compensation Compensation Total Total Adjusted Table Total Actually Paid Table Total for Actually Paid to Shareholder Shareholder Net Income Diluted Year for PEO to PEO Non-PEO NEOs Non-PEO NEOs Return Return $MM EPS ($)(a) ($)(b) ($)(c) ($)(d) ($)(e) ($)(f) ($) ($)(g) 2022 $ 26,287,185 $ 67,395,343 $ 9,125,252 $ 20,275,581 $ 209.58 $ 144.53 $ 11,836 $ 13.77 2021 23,912,154 66,387,875 11,035,630 24,203,425 168.96 134.15 11,542 11.83 2020 24,007,591 47,010,914 15,221,472 22,524,088 127.61 108.74 4,616 9.76 (a) The dollar amounts reported are the total compensation reported for Mr. Gonzalez for each fiscal year in the “Total” column of the Summary Compensation Table. (b) The dollar amounts reported represent the “compensation actually paid” to Mr. Gonzalez, who served as our PEO for each of fiscal years 2020, 2021 and 2022, as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not reflect the actual amount of compensation earned by or paid to Mr. Gonzalez during such fiscal years and are based on valuation assumptions required by the SEC, which are unlikely to reflect actual amounts realized at vesting or exercise (as applicable). In accordance with the requirements of Item 402(v) of Regulation S-K, the reported “Total” in the Summary Compensation Table for the applicable year is adjusted to determine the “compensation actually paid” amount as follows: (1) The amount reflected in the “Stock Award” and “Option Award” columns of the Summary Compensation Table with respect to each NEO has been deducted from the Summary Compensation Table Total and substituted with an equity award value for each year calculated by adding or subtracting, as applicable, the following: (i) the year-end fair value of any equity awards granted in the applicable fiscal year that are outstanding and unvested as of the end of such year, accounting for any banking of the award resulting from EPS or ROIC performance, as applicable (as reflected in footnote (2) to the Outstanding Equity Awards at Fiscal Year End Table); (ii) the change in fair value from the end of the prior fiscal year of any awards granted in prior fiscal years that are outstanding and unvested as of the end of the applicable fiscal year, accounting for any adjustment based on relative TSR performance on awards for which the performance period ends as of this date (as reflected in footnote (2) to the Outstanding Equity Awards at Fiscal Year End Table); (iii) for awards granted in prior fiscal years that vested in the applicable fiscal year, the amount equal to the change in value as of the vesting date (from the end of the prior fiscal year); and (iv) the dollar value of dividends accrued on equity awards in the applicable year prior to the vesting date (excluding option awards, which do not carry dividend equivalent rights) that are not otherwise reflected in the fair value of such award or included in any other component of total compensation for the applicable fiscal year. The valuation assumptions used to calculate fair values on equity awards other than options are the same as those disclosed at the time of grant. Stock option awards are valued using a Black-Scholes model at the time of grant (as disclosed in footnote (2) to the Summary Compensation Table on page 51) with subsequent fair value calculations performed using a Lattice model. The amounts in the following table represent each of the amounts deducted and added to the equity award values for Mr. Gonzalez for the applicable year for purposes of computing the “compensation actually paid” amounts appearing in column (b) of the pay versus performance table: Grant Date Year-end Change in Change in Total Equity Fair Value of Fair Value of Fair Value as of Fair Value as of Value Equity Awards Equity Awards Year-End of Any the Vesting Date Total Reflected in Granted Granted Prior Year of Any Prior Year Equity Value Summary During During Awards that Awards that Reflected in Compensation Applicable Applicable Remain Unvested Vested During Compensation Year PEO Name Table Year Year as of Year-End Applicable Year Actually Paid 2022 Richard A. Gonzalez $ 18,899,727 $ (18,899,727) $ 30,610,960 $ 24,678,951 $ 4,696,417 $ 59,986,328 2021 Richard A. Gonzalez 15,708,337 (15,708,337) 35,539,956 22,280,118 342,511 58,162,585 2020 Richard A. Gonzalez 14,426,658 (14,426,658) 28,865,235 9,959,203 (107,328) 38,717,110 (2) The pension benefit value reported in the “Change in Pension and Nonqualified Deferred Compensation” column of the Summary Compensation Table for each applicable year is adjusted to account for the aggregate of two components: (i) the actuarially determined service cost for services rendered by Mr. Gonzalez during the applicable year (the “service cost”); and (ii) the entire cost of benefits granted in a plan amendment during the applicable year that are attributed by the benefit formula to services rendered in periods prior to the plan amendment (the “prior service cost”), in each case, calculated in accordance with U.S. GAAP. The amounts in the following table represent each of the amounts deducted and added to the change in pension value for Mr. Gonzalez for the applicable year for purposes of computing the “compensation actually paid” amounts appearing in column (b) of the pay versus performance table: Total Change in Pension Prior Total Change in Value Reflected Change in Service Costs Service Costs Pension Value in the Summary Pension Value Attributable Introduced Reflected in Compensation for the to the During the Compensation Year PEO Name Table Applicable Year Applicable Year Applicable Year Actually Paid 2022 Richard A. Gonzalez $ 0 $ 0 $ 21,557 $ N/A $ 21,557 2021 Richard A. Gonzalez 0 0 21,474 N/A 21,474 2020 Richard A. Gonzalez 1,307,025 (1,307,025) 19,896 N/A 19,896 (c) The dollar amounts reported represent the average of the amounts reported for AbbVie’s named executive officers (NEOs) as a group (excluding the CEO) in the “Total” column of the Summary Compensation Table in each applicable fiscal year. The names of each of the NEOs included for purposes of calculating the average amounts in each applicable year are as follows: (i) for 2022, R. Michael, S. Reents, L. Schumacher, J. Stewart and A. Saleki-Gerhardt; (ii) for 2021, R. Michael, L. Schumacher, M. Severino and J. Stewart; and (iii) for 2020, R. Michael, L. Schumacher, C. Alban and M. Severino. (d) The dollar amounts reported represent the average amount of “compensation actually paid” to the NEOs as a group (excluding the CEO), as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not reflect the actual amount of compensation earned by or paid to the NEOs as a group (excluding the CEO) during such fiscal years and are based on valuation assumptions required by the SEC, which are unlikely to reflect actual amounts realized at vesting or exercise (as applicable). The average total compensation for the NEOs as a group (excluding the CEO) for each year was adjusted using the same methodology described above in footnote (b) to determine the compensation actually paid. The amounts in the following table represent the average of the amounts deducted and added to the equity award values for AbbVie’s named executive officers (NEOs) as a group (excluding the CEO) for the applicable year for purposes of computing the “compensation actually paid” amounts appearing in column (d) of the pay versus performance table: Grant Date Year-end Change in Change in Total Equity Fair Value of Fair Value of Fair Value as of Fair Value as of Value Equity Awards Equity Awards Year-End of Any the Vesting Date Total Reflected in Granted Granted Prior Year of Any Prior Year Equity Value Summary During During Awards that Awards that Reflected in Compensation Applicable Applicable Remain Unvested Vested During Compensation Year NEO Names Table Year Year as of Year-End Applicable Year Actually Paid 2022 See footnote (c) $ 5,525,171 $ (5,525,171) $ 8,474,891 $ 6,752,661 $ 1,177,799 $ 16,405,351 2021 See footnote (c) 4,877,159 (4,877,159) 11,034,439 8,140,820 118,835 19,294,094 2020 See footnote (c) 7,084,422 (7,084,422) 14,174,651 3,264,437 (27,650) 17,411,438 The amounts in the following table represent each of the amounts deducted and added to the change in pension value for AbbVie’s named executive officers (NEOs) as a group (excluding the CEO) for the applicable year for purposes of computing the “compensation actually paid” amounts appearing in column (d) of the pay versus performance table: Total Change in Pension Prior Total Change in Value Reflected Change in Service Costs Service Costs Pension Value in the Summary Pension Value Attributable Introduced Reflected in Compensation for the to the During the Compensation Year NEO Names Table Applicable Year Applicable Year Applicable Year Actually Paid 2022 See footnote (c) $ 178,790 $ (178,790) $ 448,940 $ N/A $ 448,940 2021 See footnote (c) 1,825,826 (1,825,826) 576,686 N/A 576,686 2020 See footnote (c) 3,557,054 (3,557,054) 532,653 N/A 532,653 (e) Cumulative TSR is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between AbbVie’s share price at the end and the beginning of the measurement period by AbbVie's share price at the beginning of the measurement period. (f) Represents the weighted peer group TSR, weighted according to the respective companies’ stock market capitalization at the beginning of each period for which a return is indicated. The peer group used for this purpose is the NYSE Arca Pharmaceutical Index, our peer group used for purposes of Item 201(e) of Regulation S-K. (g) As required by Item 402(v) of Regulation S-K, AbbVie has determined that Adjusted Diluted EPS is the Company Selected Measure, as it is the most important financial performance measure (that is not otherwise required to be disclosed in the table) used to link compensation actually paid to AbbVie’s NEOs to company performance for the most recently completed fiscal year. | | |
| Company Selected Measure Name | Adjusted Diluted EPS | | |
| Named Executive Officers, Footnote [Text Block] | (c) The dollar amounts reported represent the average of the amounts reported for AbbVie’s named executive officers (NEOs) as a group (excluding the CEO) in the “Total” column of the Summary Compensation Table in each applicable fiscal year. The names of each of the NEOs included for purposes of calculating the average amounts in each applicable year are as follows: (i) for 2022, R. Michael, S. Reents, L. Schumacher, J. Stewart and A. Saleki-Gerhardt; (ii) for 2021, R. Michael, L. Schumacher, M. Severino and J. Stewart; and (iii) for 2020, R. Michael, L. Schumacher, C. Alban and M. Severino. | | |
| Peer Group Issuers, Footnote [Text Block] | (f) Represents the weighted peer group TSR, weighted according to the respective companies’ stock market capitalization at the beginning of each period for which a return is indicated. The peer group used for this purpose is the NYSE Arca Pharmaceutical Index, our peer group used for purposes of Item 201(e) of Regulation S-K. | | |
| PEO Total Compensation Amount | $ 26,287,185 | $ 23,912,154 | $ 24,007,591 |
| PEO Actually Paid Compensation Amount | $ 67,395,343 | 66,387,875 | 47,010,914 |
| Adjustment To PEO Compensation, Footnote [Text Block] | (b) The dollar amounts reported represent the “compensation actually paid” to Mr. Gonzalez, who served as our PEO for each of fiscal years 2020, 2021 and 2022, as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not reflect the actual amount of compensation earned by or paid to Mr. Gonzalez during such fiscal years and are based on valuation assumptions required by the SEC, which are unlikely to reflect actual amounts realized at vesting or exercise (as applicable). In accordance with the requirements of Item 402(v) of Regulation S-K, the reported “Total” in the Summary Compensation Table for the applicable year is adjusted to determine the “compensation actually paid” amount as follows: (1) The amount reflected in the “Stock Award” and “Option Award” columns of the Summary Compensation Table with respect to each NEO has been deducted from the Summary Compensation Table Total and substituted with an equity award value for each year calculated by adding or subtracting, as applicable, the following: (i) the year-end fair value of any equity awards granted in the applicable fiscal year that are outstanding and unvested as of the end of such year, accounting for any banking of the award resulting from EPS or ROIC performance, as applicable (as reflected in footnote (2) to the Outstanding Equity Awards at Fiscal Year End Table); (ii) the change in fair value from the end of the prior fiscal year of any awards granted in prior fiscal years that are outstanding and unvested as of the end of the applicable fiscal year, accounting for any adjustment based on relative TSR performance on awards for which the performance period ends as of this date (as reflected in footnote (2) to the Outstanding Equity Awards at Fiscal Year End Table); (iii) for awards granted in prior fiscal years that vested in the applicable fiscal year, the amount equal to the change in value as of the vesting date (from the end of the prior fiscal year); and (iv) the dollar value of dividends accrued on equity awards in the applicable year prior to the vesting date (excluding option awards, which do not carry dividend equivalent rights) that are not otherwise reflected in the fair value of such award or included in any other component of total compensation for the applicable fiscal year. The valuation assumptions used to calculate fair values on equity awards other than options are the same as those disclosed at the time of grant. Stock option awards are valued using a Black-Scholes model at the time of grant (as disclosed in footnote (2) to the Summary Compensation Table on page 51) with subsequent fair value calculations performed using a Lattice model. The amounts in the following table represent each of the amounts deducted and added to the equity award values for Mr. Gonzalez for the applicable year for purposes of computing the “compensation actually paid” amounts appearing in column (b) of the pay versus performance table: Grant Date Year-end Change in Change in Total Equity Fair Value of Fair Value of Fair Value as of Fair Value as of Value Equity Awards Equity Awards Year-End of Any the Vesting Date Total Reflected in Granted Granted Prior Year of Any Prior Year Equity Value Summary During During Awards that Awards that Reflected in Compensation Applicable Applicable Remain Unvested Vested During Compensation Year PEO Name Table Year Year as of Year-End Applicable Year Actually Paid 2022 Richard A. Gonzalez $ 18,899,727 $ (18,899,727) $ 30,610,960 $ 24,678,951 $ 4,696,417 $ 59,986,328 2021 Richard A. Gonzalez 15,708,337 (15,708,337) 35,539,956 22,280,118 342,511 58,162,585 2020 Richard A. Gonzalez 14,426,658 (14,426,658) 28,865,235 9,959,203 (107,328) 38,717,110 (2) The pension benefit value reported in the “Change in Pension and Nonqualified Deferred Compensation” column of the Summary Compensation Table for each applicable year is adjusted to account for the aggregate of two components: (i) the actuarially determined service cost for services rendered by Mr. Gonzalez during the applicable year (the “service cost”); and (ii) the entire cost of benefits granted in a plan amendment during the applicable year that are attributed by the benefit formula to services rendered in periods prior to the plan amendment (the “prior service cost”), in each case, calculated in accordance with U.S. GAAP. The amounts in the following table represent each of the amounts deducted and added to the change in pension value for Mr. Gonzalez for the applicable year for purposes of computing the “compensation actually paid” amounts appearing in column (b) of the pay versus performance table: Total Change in Pension Prior Total Change in Value Reflected Change in Service Costs Service Costs Pension Value in the Summary Pension Value Attributable Introduced Reflected in Compensation for the to the During the Compensation Year PEO Name Table Applicable Year Applicable Year Applicable Year Actually Paid 2022 Richard A. Gonzalez $ 0 $ 0 $ 21,557 $ N/A $ 21,557 2021 Richard A. Gonzalez 0 0 21,474 N/A 21,474 2020 Richard A. Gonzalez 1,307,025 (1,307,025) 19,896 N/A 19,896 | | |
| Non-PEO NEO Average Total Compensation Amount | $ 9,125,252 | 11,035,630 | 15,221,472 |
| Non-PEO NEO Average Compensation Actually Paid Amount | $ 20,275,581 | 24,203,425 | 22,524,088 |
| Adjustment to Non-PEO NEO Compensation Footnote [Text Block] | (d) The dollar amounts reported represent the average amount of “compensation actually paid” to the NEOs as a group (excluding the CEO), as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not reflect the actual amount of compensation earned by or paid to the NEOs as a group (excluding the CEO) during such fiscal years and are based on valuation assumptions required by the SEC, which are unlikely to reflect actual amounts realized at vesting or exercise (as applicable). The average total compensation for the NEOs as a group (excluding the CEO) for each year was adjusted using the same methodology described above in footnote (b) to determine the compensation actually paid. The amounts in the following table represent the average of the amounts deducted and added to the equity award values for AbbVie’s named executive officers (NEOs) as a group (excluding the CEO) for the applicable year for purposes of computing the “compensation actually paid” amounts appearing in column (d) of the pay versus performance table: Grant Date Year-end Change in Change in Total Equity Fair Value of Fair Value of Fair Value as of Fair Value as of Value Equity Awards Equity Awards Year-End of Any the Vesting Date Total Reflected in Granted Granted Prior Year of Any Prior Year Equity Value Summary During During Awards that Awards that Reflected in Compensation Applicable Applicable Remain Unvested Vested During Compensation Year NEO Names Table Year Year as of Year-End Applicable Year Actually Paid 2022 See footnote (c) $ 5,525,171 $ (5,525,171) $ 8,474,891 $ 6,752,661 $ 1,177,799 $ 16,405,351 2021 See footnote (c) 4,877,159 (4,877,159) 11,034,439 8,140,820 118,835 19,294,094 2020 See footnote (c) 7,084,422 (7,084,422) 14,174,651 3,264,437 (27,650) 17,411,438 The amounts in the following table represent each of the amounts deducted and added to the change in pension value for AbbVie’s named executive officers (NEOs) as a group (excluding the CEO) for the applicable year for purposes of computing the “compensation actually paid” amounts appearing in column (d) of the pay versus performance table: Total Change in Pension Prior Total Change in Value Reflected Change in Service Costs Service Costs Pension Value in the Summary Pension Value Attributable Introduced Reflected in Compensation for the to the During the Compensation Year NEO Names Table Applicable Year Applicable Year Applicable Year Actually Paid 2022 See footnote (c) $ 178,790 $ (178,790) $ 448,940 $ N/A $ 448,940 2021 See footnote (c) 1,825,826 (1,825,826) 576,686 N/A 576,686 2020 See footnote (c) 3,557,054 (3,557,054) 532,653 N/A 532,653 | | |
| Compensation Actually Paid vs. Total Shareholder Return [Text Block] | Comparison of “Compensation Actually Paid” to TSR The chart below demonstrates that the “compensation actually paid” amounts shown for Mr. Gonzalez and average “compensation actually paid” to the other NEOs is aligned with AbbVie’s cumulative TSR over the three years presented in the pay versus performance table. The alignment of compensation actually paid with AbbVie’s cumulative TSR over the period presented reflects that a significant portion of the compensation actually paid to Mr. Gonzalez and to the other NEOs is comprised of equity awards. Moreover, AbbVie’s executive compensation philosophy and design is fundamentally based on a commitment to align pay and performance. | | |
| Compensation Actually Paid vs. Net Income [Text Block] | Comparison of “Compensation Actually Paid” to Net Income AbbVie’s net income was approximately $4.6 billion in 2020, $11.5 billion in 2021 and $11.8 billion in 2022. Mr. Gonzalez’s “compensation actually paid” was approximately $47 million, $66 million and $67 million in the corresponding years and the average “compensation actually paid” to AbbVie’s other NEOs was approximately $22.5 million, $24 million and $20 million in each of those years, respectively. AbbVie’s net income has steadily increased over the three years presented in the pay versus performance table, indicating alignment between “compensation actually paid” to Mr. Gonzalez and the other NEOs (on average) and AbbVie's net income during this period. | | |
| Compensation Actually Paid vs. Company Selected Measure [Text Block] | Comparison of “Compensation Actually Paid” to Company-Selected Measure (Adjusted Diluted EPS) AbbVie’s annualized adjusted diluted EPS was $9.76 in 2020, $11.83 in 2021 and $13.77 in 2022. Mr. Gonzalez’s “compensation actually paid” was approximately $47 million, $66 million and $67 million in the corresponding years and the average “compensation actually paid” to AbbVie’s other NEOs was approximately $22.5 million, $24 million and $20 million in each of those years, respectively. While AbbVie uses numerous financial and non-financial performance measures for the purpose of evaluating performance for our compensation programs, we have determined that adjusted diluted EPS is the financial performance measure that, in AbbVie’s assessment, represents the most important performance measure (that is not otherwise required to be disclosed in the table) used to link compensation actually paid to NEOs, for the most recently completed fiscal year, to AbbVie’s performance. AbbVie places significant emphasis on achieving positive EPS outcomes because it reflects strong operating dynamics in the underlying business, which is imperative for sustained long-term growth. | | |
| Total Shareholder Return Vs Peer Group [Text Block] | Comparative Analysis of the Pay versus Performance Table AbbVie’s compensation program is designed to attract and retain executives whose talents and contributions sustain long-term growth by aligning their interests with the drivers of stockholder returns and supporting their achievement of AbbVie’s primary business goals. AbbVie considers several performance measures to ensure executives are incentivized to accomplish these objectives, many of which are not presented in the pay versus performance table. The charts and descriptions below explain the relationship between the columns presented in the pay versus performance table. AbbVie TSR versus Peer Group TSR The graph below shows AbbVie’s cumulative TSR over the three-year period ending with December 31, 2022 as compared to the NYSE Arca Pharmaceutical Index. AbbVie’s cumulative TSR consistently outperformed our peer group during the three years presented in the table. Additionally, AbbVie is committed to a robust return of capital to stockholders with an increase of 270% in its quarterly dividend since 2013 as part of a balanced and disciplined capital allocation program, contributing to our strong cumulative TSR. | | |
| Tabular List [Table Text Block] | Most Important Performance Measures The performance measures that AbbVie uses in our executive compensation program are selected based on the objective of incentivizing NEOs to achieve long-term, sustainable growth in stockholder value. As required by Item 402(v) of Regulation S-K, we have identified the following financial performance measures as being the most important in linking actual compensation paid to executives to AbbVie’s performance. Adjusted Diluted Earnings Per Share Adjusted Relative Return on Invested Capital Adjusted Return on Assets Non-GAAP Income Before Taxes Non-GAAP Operating Margin Platform Revenue Total Shareholder Return | | |
| Total Shareholder Return Amount | $ 209.58 | 168.96 | 127.61 |
| Peer Group Total Shareholder Return Amount | 144.53 | 134.15 | 108.74 |
| Net Income (Loss) | $ 11,836,000,000 | $ 11,542,000,000 | $ 4,616,000,000 |
| Company Selected Measure Amount | 13.77 | 11.83 | 9.76 |
| PEO Name | Mr. Gonzalez | | |
| Measure [Axis]: 1 | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Measure Name | Adjusted Diluted Earnings Per Share | | |
| Non-GAAP Measure Description [Text Block] | (g) As required by Item 402(v) of Regulation S-K, AbbVie has determined that Adjusted Diluted EPS is the Company Selected Measure, as it is the most important financial performance measure (that is not otherwise required to be disclosed in the table) used to link compensation actually paid to AbbVie’s NEOs to company performance for the most recently completed fiscal year. | | |
| Measure [Axis]: 2 | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Measure Name | Adjusted Relative Return on Invested Capital | | |
| Measure [Axis]: 3 | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Measure Name | Adjusted Return on Assets | | |
| Measure [Axis]: 4 | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Measure Name | Non-GAAP Income Before Taxes | | |
| Measure [Axis]: 5 | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Measure Name | Non-GAAP Operating Margin | | |
| Measure [Axis]: 6 | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Measure Name | Platform Revenue | | |
| Measure [Axis]: 7 | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Measure Name | Total Shareholder Return | | |
| PEO [Member] | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Equity Awards | $ 18,899,727 | $ 15,708,337 | $ 14,426,658 |
| Pension | 0 | 0 | 1,307,025 |
| PEO [Member] | Grant Date Fair Value of Equity Awards Granted During Applicable Year | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | (18,899,727) | (15,708,337) | (14,426,658) |
| PEO [Member] | Total Equity Value Reflected in Compensation Actually Paid | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | 59,986,328 | 58,162,585 | 38,717,110 |
| PEO [Member] | Year-end Fair Value of Equity Awards Granted During Applicable Year | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | 30,610,960 | 35,539,956 | 28,865,235 |
| PEO [Member] | Change in Fair Value as of Year-End of Any Prior Year Awards that Remain Unvested as of Year-End | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | 24,678,951 | 22,280,118 | 9,959,203 |
| PEO [Member] | Change in Fair Value as of the Vesting Date of Any Prior Year Awards that Vested During Applicable Year | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | 4,696,417 | 342,511 | (107,328) |
| PEO [Member] | Total Change in Pension Value Reflected in Compensation Actually Paid | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | 21,557 | 21,474 | 19,896 |
| PEO [Member] | Service Costs Attributable to the Applicable Year | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | 21,557 | 21,474 | 19,896 |
| PEO [Member] | Change in Pension Value for the Applicable Year | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | 0 | 0 | (1,307,025) |
| Non-PEO NEO [Member] | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Equity Awards | 5,525,171 | 4,877,159 | 7,084,422 |
| Pension | 178,790 | 1,825,826 | 3,557,054 |
| Non-PEO NEO [Member] | Grant Date Fair Value of Equity Awards Granted During Applicable Year | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | (5,525,171) | (4,877,159) | (7,084,422) |
| Non-PEO NEO [Member] | Total Equity Value Reflected in Compensation Actually Paid | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | 16,405,351 | 19,294,094 | 17,411,438 |
| Non-PEO NEO [Member] | Year-end Fair Value of Equity Awards Granted During Applicable Year | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | 8,474,891 | 11,034,439 | 14,174,651 |
| Non-PEO NEO [Member] | Change in Fair Value as of Year-End of Any Prior Year Awards that Remain Unvested as of Year-End | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | 6,752,661 | 8,140,820 | 3,264,437 |
| Non-PEO NEO [Member] | Change in Fair Value as of the Vesting Date of Any Prior Year Awards that Vested During Applicable Year | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | 1,177,799 | 118,835 | (27,650) |
| Non-PEO NEO [Member] | Total Change in Pension Value Reflected in Compensation Actually Paid | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | 448,940 | 576,686 | 532,653 |
| Non-PEO NEO [Member] | Service Costs Attributable to the Applicable Year | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | 448,940 | 576,686 | 532,653 |
| Non-PEO NEO [Member] | Change in Pension Value for the Applicable Year | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | $ (178,790) | $ (1,825,826) | $ (3,557,054) |
